

AUSTERE

Life Science LTD

2nd Floor, 21 Skylines Village Limeharbour, London England E149TS - UK Ph: +44 7424 550 490

Innovations for Life



For effective treatment of allergic rhinitis

ntranase

Well tolerated & safe in children above 4 years

The ace that keeps rhinitis away

Effective agent for the treatment of allergic & non-allergic rhinitis² Proven ef \square cacy in the regression of nasal polyps & also as adjuvant to polypectomy to prevent nasal polyp recurrence

Indications:

- ♦ Nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older.
- Vasomotor rhinitis
- Symptomatic relief of nasal polyposis
- Prevention of nasal polyposis after polypectomy

2. Drugs 1997; 53(5): 885-907



Intranase-AZ® Nasal Spray

Azelastine Hydrochloride 140mcg + Fluticasone Propionate 50mcg

Effective treatment for

- Nasal congession
- Runny/itching/stuffy nose
- Sneezing
- Seasonal allergies

According to ARIA guidelines
Intranase-AZ® (antihistmine+ corticosteroid) is
recommended all the stages of AR treatment





Innovations for delivering solutions

THE BENEFITS OF CONVENIENCE AND PRODUCT INTEGRITY

- APTAR valve ensures international standard of drug delivery
- Innovative and patient-focused drug delivery solutions for your prescription medicines.
- Intranase provides full protection of the content, and most important for the final user, is easy to use and highly convenient.
- Intranase offers protection of sensitive ingredients, avoidance of any contamination, and better hygiene.
- Innovation at the core, driving patient-focused drug delivery solutions



Coming from US FDA Approved Manufacturing Plant

Clearing the airways...





- Superior Mucolytic
- Indian clinical experience
- Better Compliance
- Potent antioxidant



- Sugar free safe in diabetic patients
- Effervescent tablets improved GI tolerability
- Orange flavour better masking of the drug taste







- Safe and well-tolerated
- Seasonal Allergic Rhinitis
- Perennial Allergic Rhinitis
- Allergic Rhinitis co-existing with Asthma
- Asthma




Desloratadine & Montelukast Tablets





Desloratadine
improves quality
of life and symptom
severity in patients
with allergic
rhinitis.

Food Does Not Alter the Oral Bioavailability of Desloratadine randomised, open-label, single-dose, 2-way crossover study(n=18)



Gupta S et al. Clin Pharamacokinet.2002;41(Suppl 1): 7-12. Prof DR Ariyanto Harsono SpAK 53

Abstract BACKGROUND

Desloratadine is associated with decreased signs and symptoms and improved nasal airflow in multiple clinical trials in patients with allergic rhinitis (AR). The effect of desloratadine on quality of life (QOL) in AR has not been widely reported to date. We compared the effects of desloratadine and placebo on QOL in seasonal AR using validated, disease-specific measures.

METHODS

This was a multicenter, double-blind, randomized, parallel-group study of desloratedine 5 mg or placebo daily for 2 weeks in patients with symptomatic seasonal AR. QOL was assessed at baseline and at day 14 using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). AR signs/symptoms and the global response to therapy were measured at baseline and at day 14; signs/symptoms were also rated AM/PM in patient diaries. Adverse events (AE) were recorded.

RESULTS

Overall 234 patients received desloratedine and 249 received placebo. At day 14 desloratedine was associated with a significantly larger improvement from baseline in the mean total RQLQ score vs placebo (P = 0.0003). Desloratedine also led to significant improvements from baseline in all RQLQ sub-domains (P < or = 0.043). At day 14 significant decreases from baseline were noted in the desloratedine group for total nasal (P = 0.0003), total non-nasal (P = 0.001) and total symptoms scores (P = 0.0001). Morning AR symptoms were significantly decreased in the desloratedine group after 1 day of treatment. Desloratedine was well tolerated, with an AE rate similar to placebo.

CONCLUSION

Significant reductions in signs and symptoms of AR with deslorated ine treatment were accompanied by improved disease-specific QOL measures. (Less)

VASHOFF Sinus Rinse

Sodium Chloride Powder for Nasal Solution 4g/200ml

- Rhinosinusitis
- Viral upper respiratory infections
- Allergic rhinitis
- Atrophic rhinitis
- Fungal rhinosinusitis
- Nasal congestion
- Post-operative conditions (especially after Functional Endoscopic Sinus Surgery i.e. FESS)

Dosage

- Saline nasal irrigation can be done once or twice a day. However, the dosage and duration of use may vary depending on the condition for which it is used.
- Saline nasal irrigation can be done anytime of the day. However, it is recommended that nasal washing is done at least one hour before going to bed.





In URTI with Fever, LRTI



Cefpodoxime Proxetil 200 mg Clavulanic Acid 125mg Tablets

- Highly efficacious in the treatment of Typhoid fever
- Effective against multi drug resistant Salmonella Typhi
- Destroys DNA gyrase mutant trains through cell wall lysis
- Higher Dissolution rate
- Higher Bioavailability
- Higher Efficacy









- Maintains 24 hrs acid control
- High Healing rate compared to other PPIs
- Convenient dosage
- Lasting relief from acid secretion
- Economic substitute for your current PPI
- * **Precautions**: **ZILA**[®] (**Ilaprazole IP Tablets**) should not be prescribed to individuals who are allergic to other PPIs.

Other Drug Interactions: ZILA (Ilaprazole IP Tablets) may interact with Clarithromycin, maidazolam, ketoconazole and amoxicillin

Dosage: The recommended adult dosage of **ZILA** (**Ilaprazole IP Tablets**) is 5-20 mg/day, Food(before/after)

ZILA (Ilaprazole IP Tablets) should be taken at least 30 minutes before food intake Food and Drug Administration (FDA) approved .Prescription Only (POM)





ZILA (Ilaprazole-10 mg IP Tablets)

for the Treatment of Gastroesophageal Reflux Disease (GERD)

*Gastroenterology & Hepatology / *Gastroesophageal reflux disease (GERD)

ZILA (Ilaprazole IP Tablets) is a proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It is available in strengths of 10 mg.

ZILA (**Ilaprazole IP Tablets**), a novel proton pump inhibitor (PPI), is used for the treatment of gastroesophageal reflux disorders (GERD), dyspepsia and peptic ulcers. Pharmacokinetics: After oral administration, the drug is rapidly absorbed. The drug is extensively metabolized to Ilaprazole sulfone via the CYP450 enzymes. The drug is primaily excreted in the urine as drug metabolites and unchanged drug to some extent.

ZILA (**Ilaprazole IP Tablets**), significantly prevents thedevelopment of reflux oesophagitis and gastric secretion in a dose-dependent manner,

In Gastroesophageal Reflux Disease (GERD)

Ulciquick

Pantoprazole 40mg Tablets

The stable proton pump inhibitor

- Maintains 24 hrs acid control
- High Healing rate compared to other PPIs
- Convenient dosage
- · Lasting relief from acid secretion
- · No risk of drug interaction







Mucosal Damage

New and emerging treatment options for Neuropathic pain from diabetic Neuropathy





More potent successor to gabapentin

- Diabetic Neuropathy and neuralgia
- Post-herpetic neuralgia
- Fibromyalgia





Better absorption





For long term steroid usage in inflammation

Austacort

Deflazacort 6mg Tablets

As effective as other corticosteroids** with significantly lesser side effects

- Significantly lower diabetogenic effects 1,2
- Significantly lesser Bone loss compared to Prednisolone Accumulation of fat mass4
- Less growth suppression as compared to Methylprednisolone in children3
- * ILD : Interstitial Lung disease** Methylprednisolone & Prednisolone
- 1. Pagono A, Bruno A et. al; Arch intern med 1989;149;1098-101,
- Markham A, Bryson H; Drugs 1995;50(2); 317-333
- Anthony Markham and Harriet M. Bryson; A review of its pharmacological properties and therapeutic efficacy: drugs 50(2) 1995 Page: 228-229, 330
- 4. Lippuner K, Kasaz JP, J Clim Endocrinol Metab; 1998; 198:3795-3802.
- 5. Drugs 1995;50;2



Two Vital combination of Serratiopeptidase & Diclofenac Potassium for better Therapeutic response




Serratiopeptidase 10mg Diclofenac potassium 50mg tablets


- · Increases concentration of Diclofenac at the site of injury
- Acts on all types of inflammatory agents Controls-Edema, Swelling, Pain & inflammation
- · Enhances the migration of microphage
- Provides better analgesic
- · Well tolerated and anti-pyretic















Cissus Quadrangularis 500mg + Calcium Citrate Malate 250 mg + Vitamin K2 45mg + Vitamin D3 1000 I.U. Tablets

- Reduction of bone fracture healing period
- + Fracture with site of low blood supply for faster healing
- Pathological Fracture
- Osteoporotic fracture
- + Reduce ambulatory period
- Early achievement of normal tensile strength
- + Better retention of Prosthesis
- Early osseointegration

Vitamin K2

This Vitamin helps the body get calcium in the right place (i.e., into the bone structures instead of the arterial vessel walls). This Helps Vitamin K2, along with calcium, maintain the body's bone mas and promote elasticity of blood vessels.

Vitamin D3

Vitamin D promotes the absorption of calcuim and phosphprus, and supports the production of several proteins involved in calcium absorption and storage. Studies have also shown the combination of calcium and vitamin D to have other benefits.

The Bonding expert





Cissus Quadrangularis 500mg + Calcium Citrate Malate 250 mg + Vitamin K2 45mg + Vitamin D3 1000 I.U. Tablets

Frax plus has greater impact on osteoblastic proliferation.cissus quandrangularis builds up the chemical compositions of the fractured bone namely its mucopolysaccharides,collagen,calcium,phosphorous and others as well as its functional efficiency.



The European Food Safety Authority has concluded that calcium citrate malate is "more bioavailable" than other forms of calcium supplementation.



Mucopolysaccharides play an important role in the healing by supplying raw materials for repairs.so greater the accumulation of these materials more rapid will be the rate of healing. Rapid the utilization of these raw metrials earlier will be completion of healing process.

The Bonding expert



Redefine control in type 2 diabetes

RAUSTAMET GIG2

Metformin XR 500mg + Glimepiride 1mg / 2mg

Tablets

Increases significantly the ratio between C-peptide/Glucose3


Hydrophillic


polymer

martix

technology

Greater proportion of Patients achieved HbA 1c target with Glimepiride group than with Sitagliptin group ¹





In Combination Therapy Vs Monotherapy:

Significantly improves HbA1c, FPG PPHG² Improves Lipid Profile²







For management of Hypertention/CV risk reduction





Effective Sartan

- \heartsuit Partial PPAR γ agonist unlike other sartans, thus significantly improves insulin sensitivity, FPG, Hba1c levels and lipid profile
- Significantly greater BP reduction than ramipin, Losartan and Valasartan druing the crucial 6-hours of dosing intervel
- Fifective in preventing CVD in high risk patients
- Significantly reduces BP by 19/7.3 mm Hg in diabetic hypertensives along with improving insulin resistance.
- Significantly greater improvement in renal function and blood glucose levels than olmesartan or Losartan in diabetic hypertensives



In the Management of Dyslipidemia and CV Risk

Raus Eall Market Atorvastatin 10mg/20mg Tablets

Trusted statin Worldwide

Completely halls the progression of atherosclerosis in CHD patients

 Significant 36% reduction in CV events in hypertensives with normal levels of cholesterol

Austalip

Majority of type 2 diabets patients attain LDL-C goal with 10mg atrovastatin



For the long term treatment of Diabetes Mellitus

RAUSTAZIDE-M Metformin Hydrochloride 500mg + Gliclazide 80mg SR Tablets

The combination that matters...

- Lowers FPG and HbA1c
- Significant improvement in Glycemic control
- Significant improvement in plasma glucose level
- Decreases LDL cholesterol
- Potential benefits in terms of improvements in specific lipid abnormalities







Life Science LTD

2nd Floor, 21 Skylines Village Limeharbour, London England E149TS - UK Ph: +44 7424 550 490

India:-

No. 319, Building No. 5/B, Sharmjivan Wadala Truck Terminal Wadala (E), Mumbai - 400 037 Email: austerpharmakl@gmail.com

